Volanesorsen · Waylivra
RNA / oligonucleotide
Also known as ISIS 304801
Evidence outlook
Approved: Waylivra (PTC Therapeutics): familial chylomicronemia syndrome (FCS) (BR)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Reliable signal
Also in development:Severe Hypertriglyceridemia · Phase 3 · investigational in the US
Also approved (2)
- Waylivra (PTC Therapeutics): familial chylomicronemia syndrome (FCS)
- Genetically confirmed familial chylomicronemia syndrome at high risk of pancreatitis (conditional)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02211209 NCT02211209 · Familial Chylomicronemia Syndrome This was a randomized, quadruple-blind, placebo-controlled trial of 67 participants, with 33 assigned to volanesorsen and 34 to placebo. The primary endpoint, percent change in fasting triglycerides at 3 months, favored volanesorsen and was statistically significant (p<0.0001), supporting strong evidence from this trial design. Registry: NCT02211209 | 3 | Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months) 2016-12-19 | Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Familial Chylomicronemia Syndrome: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Volanesorsen (Waylivra): this drug | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Reliable signal | NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5) | |
| Olezarsen (Tryngolza) | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. | |
| Plozasiran (Redemplo) | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) | |
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.